More bad news for the “new” Ironwood

Ironwood Pharma's MD-7246 flunks mid-stage study in IBS-D
May 27, 2020 8:38 AM ETIronwood Pharmaceuticals, Inc. (IRWD)By: Mamta Mayani, SA News Editor

• A Phase II trial evaluating Ironwood Pharmaceuticals' (NASDAQ:IRWD) MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D) failed to achieve its primary or key secondary endpoints.
• Patients taking MD-7246 experienced no clinically meaningful effect on bowel function.
• However, MD-7246 was generally well-tolerated and most adverse events were mild to moderate in severity.
• Based on these findings, Ironwood and collaboration partner AbbVie (NYSE:ABBV) plan to discontinue the development of MD-7246.
• Ironwood and AbbVie are now further examining the MD-7246 Phase II data in IBS-D to understand the discordance with the improvement in pain observed in the previous IBS-C results.
• Shares are down 12% premarket.

 

pack your bags, this is not good

 

So let me get this straight. In one day we’ve managed to:
Decrease the value of our pipeline
Debunk our MOA story
Undermine our pain story...we’re now just a super laxative....
Well done! Looks like we’ll see someone promoted to VP by the end of the week!

 

Who said anything about pain or super laxatives? Yes, it appears the MD-7246 MOA was debunked in yesterday’s readout as the pipeline also lost value. Anything else you want to add, smart guy?

 

Yes...with little impact on pain absent of BMs, it’s simply an oral enema...